Cambrex Recognized in 2020 CMO Leadership Awards
East Rutherford, NJ – March 26, 2020 – Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it had been recognized across six categories in the annual CMO (Contract Manufacturing Organization) Leadership Awards.
Cambrex has received CMO awards for six consecutive years, and this year, has been recognized in the following categories: Capabilities, Compatibility, Expertise, Quality, Reliability, and Service. Cambrex was given additional recognition as a CMO Leadership Award Champion for scoring as a top performer in comparison to the weighted average of other CMOs included in ISR’s annual Contract Manufacturing Quality Benchmarking survey.
“Cambrex is once again honored to be recognized as a leading supplier to the pharmaceutical industry,” commented Steven Klosk, Chief Executive Officer at Cambrex. He added, “The recent completion of our acquisition by an affiliate of Permira Funds kicks off the next exciting phase of growth for our company and we look forward to working with the Permira team to further enhance our best-in-class capabilities, strengthen our market-leading position, and to broaden and deepen our customer relationships.”
“Today more than ever, the assortment of services and partnership models CMOs provide biopharma companies of all sizes play a critical role within the global drug development and manufacturing industry,” says Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma.
Established in 2011, the CMO Leadership Awards recognize top outsourcing partners, determined by feedback from sponsor companies who outsource manufacturing. The awards are presented by Life Science Leader magazine and Industry Standard Research.
Cambrex is the leading small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. The company provides customers with an end-to-end partnership for the research, development and manufacture of small molecule therapeutics. With over 35 years’ experience and a growing team of over 2,000 experts servicing global clients from sites in North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and dosage form development and manufacturing.
Cambrex offers a range of specialist drug substance technologies and capabilities including biocatalysis, continuous flow, controlled substances, solid state science, material characterization and highly potent APIs. In addition, Cambrex can support conventional dosage forms including oral solids, semi-solids and liquids and has the expertise to manufacture specialist dosage forms such as modified-release, fixed dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile and non-sterile ointments.